NO20084053L - Inhibition of tumor growth - Google Patents

Inhibition of tumor growth

Info

Publication number
NO20084053L
NO20084053L NO20084053A NO20084053A NO20084053L NO 20084053 L NO20084053 L NO 20084053L NO 20084053 A NO20084053 A NO 20084053A NO 20084053 A NO20084053 A NO 20084053A NO 20084053 L NO20084053 L NO 20084053L
Authority
NO
Norway
Prior art keywords
tumor growth
inhibition
lytic
vaccination
establishment
Prior art date
Application number
NO20084053A
Other languages
Norwegian (no)
Inventor
Oystein Rekdal
John Sigurd Svendsen
Baldur Sveinbjornsson
Gerd Berge
Live Tone Eliassen
Original Assignee
Lytix Biopharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lytix Biopharma As filed Critical Lytix Biopharma As
Publication of NO20084053L publication Critical patent/NO20084053L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Foreliggende oppfinnelse tilveiebringer anvendelse av en lytisk forbindelse, spesielt et lytisk peptid, for fremstilling av et medikament for å fremkalle adaptiv immunitet mot tumorvekst eller etablering hos et individ, så vel som metoder for kreftbehandling og vaksinasjon.The present invention provides the use of a lytic compound, especially a lytic peptide, for the preparation of a medicament for inducing adaptive immunity to tumor growth or establishment in an individual, as well as methods of cancer treatment and vaccination.

NO20084053A 2006-03-21 2008-09-24 Inhibition of tumor growth NO20084053L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0605685.7A GB0605685D0 (en) 2006-03-21 2006-03-21 Inhibition of tumour growth
PCT/GB2007/000993 WO2007107748A2 (en) 2006-03-21 2007-03-21 Inhibition of tumour growth

Publications (1)

Publication Number Publication Date
NO20084053L true NO20084053L (en) 2008-11-28

Family

ID=36383910

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084053A NO20084053L (en) 2006-03-21 2008-09-24 Inhibition of tumor growth

Country Status (8)

Country Link
EP (1) EP2010204A2 (en)
JP (1) JP2009530359A (en)
CN (1) CN101466391A (en)
AU (1) AU2007228574B2 (en)
CA (1) CA2646589C (en)
GB (1) GB0605685D0 (en)
NO (1) NO20084053L (en)
WO (1) WO2007107748A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0821616D0 (en) * 2008-11-26 2008-12-31 Lytix Biopharma As Compounds
GB201401877D0 (en) * 2014-02-04 2014-03-19 Univ Tromsoe Peptides
JP6813258B2 (en) * 2014-12-11 2021-01-13 リティックス バイオファーマ エイエス Chemotherapy combination
JP6767096B2 (en) 2014-12-11 2020-10-14 リティックス バイオファーマ エイエス Combination of immune checkpoint inhibitors
JP2018505223A (en) * 2015-02-12 2018-02-22 ザ ジョンズ ホプキンス ユニバーシティー Method of inhibiting YAP for disrupting tumor tolerance
GB201601868D0 (en) 2016-02-02 2016-03-16 Lytix Biopharma As Methods

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE127838T1 (en) * 1987-07-06 1995-09-15 Univ Louisiana State INHIBITION OF EUKARYOTIC PATHOGENS AND NEOPLASMS WITH LYTIC PEPTIDES.
US5861478A (en) * 1987-07-06 1999-01-19 Helix Biomedix, Inc. Lytic peptides
US5773413A (en) * 1993-06-04 1998-06-30 Demeter Biotechnologies, Ltd. Method of combating mammalian neoplasias, and lytic peptides therefor
IL113244A0 (en) * 1994-04-08 1995-07-31 Demeter Biotech Ltd Method of combating mammalian neoplasia and lytic peptides therefor
GB9818938D0 (en) * 1998-08-28 1998-10-21 Alpharma As Bioactive peptides

Also Published As

Publication number Publication date
EP2010204A2 (en) 2009-01-07
CA2646589A1 (en) 2007-09-27
WO2007107748A2 (en) 2007-09-27
JP2009530359A (en) 2009-08-27
AU2007228574A1 (en) 2007-09-27
CN101466391A (en) 2009-06-24
WO2007107748A3 (en) 2007-12-06
GB0605685D0 (en) 2006-05-03
CA2646589C (en) 2016-05-03
AU2007228574B2 (en) 2013-06-20

Similar Documents

Publication Publication Date Title
DOP2021000147A (en) THERAPEUTIC COMBINATION COMPRISING LAMIVUDINE
AU2018256546A1 (en) Combination therapy with peptide epoxyketones
ES2563646T3 (en) Compositions and methods related to protein A (SpA) variants
MX2020008616A (en) Sublingual fentanyl spray.
PA8852901A1 (en) PROTEIN CINASE INHIBITORS
NO20084053L (en) Inhibition of tumor growth
MX2013003634A (en) Polycyclic heterocycle derivatives and methods of use thereof for the treatment of viral diseases.
DOP2011000264A (en) AMINOTETRALINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USES IN THERAPY
NO20074824L (en) Extension of time to disease progression or survival in cancer patients
EA201290131A1 (en) Derivatives of Purine or Deazapurine for Use in the Treatment of Viral Infections and Other Diseases
WO2008083239A3 (en) Compositions and methods for stimulating an immune response
WO2007120673A3 (en) Immunogenic wt-1 peptides and methods of use thereof
WO2011035205A3 (en) Antibodies against candida, collections thereof and methods of use
MX365205B (en) Lyophilized preparations of melphalan flufenamide.
MX2013003060A (en) Combination therapy for treating hcv infection.
UA111599C2 (en) COMPOSITION OF CASPOFUNGIN
MX2009012922A (en) Intradermal hpv peptide vaccination.
MX2013004906A (en) Novel specific hcv ns3 protease inhibitors.
MX2020009150A (en) Cpg amphiphiles and uses thereof.
ATE455789T1 (en) SUBSTITUTED NONADEPSIPEPTIDES
WO2007138382A3 (en) Cyclic peptides for modulating growth of neo-vessels and their use in therapeutic angiogenesis
EA201390925A1 (en) DERIVATIVES OF SANGLIFERIN AND METHODS OF THEIR PRODUCTION
UA102274C2 (en) Epitope peptid rab6kifl/kif20a and vaccines containing it
WO2007076091A3 (en) Treatment of viral infections using a tissue factor inhibitor
GB201018125D0 (en) Peptide

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application